Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
Exicure (Nasdaq: XCUR) has secured Patent No. 2018388302 from the Australian Patent Office for its 'GPCR Heteromer Inhibitors and Uses Thereof.' The patent covers a novel combination approach to cancer treatment targeting CXCR4 and GPCRx.
The patent supports Exicure's ongoing Phase 2 clinical trial (NCT05561751) evaluating the combination of GPC-100 and propranolol in multiple myeloma patients. The method aims to enhance hematopoietic stem cell mobilization through co-targeting CXCR4 and ADRB2, potentially improving the efficacy of CXCR4 inhibitors like GPC-100.
The patent has already been granted in the United States, Japan, and Taiwan, with applications pending in other jurisdictions.
Exicure (Nasdaq: XCUR) ha ottenuto il Brevetto n. 2018388302 dall'Ufficio Brevetti Australiano per i suoi 'Inibitori di Eteromeri GPCR e i loro Usi.' Il brevetto copre un nuovo approccio combinato al trattamento del cancro mirato a CXCR4 e GPCRx.
Il brevetto supporta il trial clinico di Fase 2 (NCT05561751) in corso di Exicure, che valuta la combinazione di GPC-100 e propranololo in pazienti affetti da mieloma multiplo. Il metodo mira a migliorare la mobilizzazione delle cellule staminali ematopoietiche attraverso il co-targeting di CXCR4 e ADRB2, potenzialmente migliorando l'efficacia degli inibitori di CXCR4 come GPC-100.
Il brevetto è già stato concesso negli Stati Uniti, in Giappone e a Taiwan, con domande in attesa in altre giurisdizioni.
Exicure (Nasdaq: XCUR) ha obtenido la Patente n. 2018388302 de la Oficina de Patentes de Australia para sus 'Inhibidores de Heterómeros GPCR y sus Usos.' La patente cubre un nuevo enfoque combinado para el tratamiento del cáncer que se dirige a CXCR4 y GPCRx.
La patente apoya el ensayo clínico de Fase 2 (NCT05561751) en curso de Exicure, que evalúa la combinación de GPC-100 y propranolol en pacientes con mieloma múltiple. El método tiene como objetivo mejorar la movilización de células madre hematopoyéticas mediante el co-targeting de CXCR4 y ADRB2, lo que podría mejorar la eficacia de los inhibidores de CXCR4 como GPC-100.
La patente ya ha sido concedida en Estados Unidos, Japón y Taiwán, con solicitudes pendientes en otras jurisdicciones.
Exicure (Nasdaq: XCUR)는 호주 특허청으로부터 'GPCR 이종체 억제제 및 그 용도'에 대한 특허 번호 2018388302를 취득했습니다. 이 특허는 CXCR4 및 GPCRx를 목표로 하는 암 치료를 위한 새로운 조합 접근 방식을 다룹니다.
이 특허는 Exicure의 진행 중인 2상 임상 시험 (NCT05561751)을 지원하며, 이는 다발성 골수종 환자에서 GPC-100과 프로프라놀롤의 조합을 평가합니다. 이 방법은 CXCR4와 ADRB2를 동시에 타겟팅하여 조혈 줄기 세포의 동원 능력을 향상시키고, GPC-100과 같은 CXCR4 억제제의 효능을 개선할 가능성이 있습니다.
이 특허는 이미 미국, 일본, 대만에서 승인되었으며, 다른 관할권에서도 신청이 진행 중입니다.
Exicure (Nasdaq: XCUR) a obtenu le Brevet n° 2018388302 de l'Office Australien des Brevets pour ses 'Inhibiteurs d'Hétéromères GPCR et leurs Utilisations.' Le brevet couvre une approche combinée novatrice pour le traitement du cancer ciblant CXCR4 et GPCRx.
Le brevet soutient l'
Le brevet a déjà été accordé aux États-Unis, au Japon et à Taïwan, avec des demandes en attente dans d'autres juridictions.
Exicure (Nasdaq: XCUR) hat das Patent Nr. 2018388302 vom Australischen Patentamt für seine 'GPCR-Heteromer-Inhibitoren und deren Verwendung' erhalten. Das Patent deckt einen neuartigen Kombinationsansatz zur Krebsbehandlung ab, der auf CXCR4 und GPCRx abzielt.
Das Patent unterstützt die laufende Phase-2-Studie (NCT05561751) von Exicure, die die Kombination von GPC-100 und Propranolol bei Patienten mit multiplem Myelom bewertet. Die Methode zielt darauf ab, die Mobilisierung von hämatopoetischen Stammzellen durch das gleichzeitige Targeting von CXCR4 und ADRB2 zu verbessern, was potenziell die Wirksamkeit von CXCR4-Inhibitoren wie GPC-100 steigern könnte.
Das Patent wurde bereits in den Vereinigten Staaten, Japan und Taiwan erteilt, während Anträge in anderen Jurisdiktionen noch ausstehen.
- Patent granted in Australia strengthens intellectual property portfolio
- Patent protection already secured in major markets (US, Japan, Taiwan)
- Technology supports ongoing Phase 2 clinical trial
- None.
The newly granted patent supports Exicure’s ongoing Phase 2 clinical trial (NCT05561751), which evaluates the combination of GPC-100 and propranolol in multiple myeloma patients. This method aims to improve hematopoietic stem cell mobilization by co-targeting CXCR4 and ADRB2, thereby enhancing the efficacy of CXCR4 inhibitors like GPC-100.
“This issuance reinforces the exclusivity of our lead clinical program,” said Andy Yoo, CEO of Exicure, Inc. “By co-targeting CXCR4 and ADRB2, we can significantly enhance the potency of CXCR4 inhibitors like GPC-100. This opens new possibilities for these inhibitors to become more effective therapies, and our well-devised patent portfolio ensures strong intellectual property protection for this proprietary approach.”
This patent family has already been granted in
About Exicure, Inc.
Exicure, Inc. has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. Following its recent restructuring and suspension of clinical and development activities, the Company is exploring strategic alternatives to maximize stockholder value, both with respect to its historical biotechnology assets and more broadly. For further information, see www.exicuretx.com.
Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. There can be no assurance regarding our ability to comply with the Panel’s decision and the applicable listing criteria by the deadline or thereafter. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual outcomes to differ materially from the outcomes expressed or implied by this report. Such risks include, among others, the possibility we will not be able to cure existing listing deficiencies, the possibility of additional deficiencies, the risk that the Company may not adequately comply with the terms of the Panel’s decision, and the risk that Nasdaq will ultimately delist the Company’s common stock. All such factors are difficult to predict and may be beyond the Company’s control. The Company undertakes no obligation and does not intend to update or revise any forward-looking statements contained herein, except as required by law or regulation. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this report.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313950375/en/
Media Contact:
Sarah Ellinwood, PhD
Kendall Investor Relations
sellinwood@kendallir.com
Source: Exicure, Inc.
FAQ
What is the significance of Exicure's new Australian patent for XCUR investors?
Which countries have granted patents for Exicure's GPCR Heteromer Inhibitors technology?
What is the current stage of Exicure's GPC-100 clinical development?
How does Exicure's patented technology work in cancer treatment?
